PT - JOURNAL ARTICLE AU - Vanhems, Philippe AU - Gustin, Marie-Paule AU - Elias, Christelle AU - Henaff, Laetitia AU - Dananché, Cédric AU - Grisi, Beatrice AU - Marion, Elodie AU - Khanafer, Nagham AU - Hilliquin, Delphine AU - Gardes, Sophie AU - Gerbier-Colomban, Solweig AU - Amour, Selilah AU - Kuczewski, Elisabetta AU - Escuret, Vanessa AU - Lina, Bruno AU - Saadatian-Elahi, Mitra TI - Clinical characteristics and factors associated with admission to intensive care units in hospitalized COVID-19 patients in Lyon University Hospitals, France AID - 10.1101/2020.06.09.20125286 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.09.20125286 4099 - http://medrxiv.org/content/early/2020/06/12/2020.06.09.20125286.short 4100 - http://medrxiv.org/content/early/2020/06/12/2020.06.09.20125286.full AB - Introduction A new respiratory virus, SARS-CoV-2, has emerged and spread worldwide since late 2019. This study aims at analyzing clinical presentation on admission and the determinants associated with direct admission or transfer to intensive care units (ICUs) in hospitalized COVID-19 patients.Patients and Methods In this prospective hospital-based study, socio-demographic, clinical and biological characteristics, on admission, of adult COVID-19 hospitalized patients were prospectively collected and analyzed. The outcome was admission/transfer to intensive care units compared with total hospital stay in medical wards according to patient characteristics.Results Of the 412 patients included, 325 were discharged and 87 died in hospital. Multivariable regression showed increasing odds of admission/transfer to ICUs with male gender (OR, 1.99 [95%CI, 1.07-3.73]), temperature (OR, 1.37 [95% CI, 1.01-1.88] per degree Celsius increase), abnormal lung auscultation on admission (OR, 2.62 [95% CI, 1.40-4.90]), elevated level of CRP (OR, 6.96 [95% CI, 1.45-33.35 for CRP>100mg/L vs CRP<10mg/L). Increased time was observed between symptom onset and hospital admission (OR, 4.82 [95% CI, 1.61-14.43] for time >10 days vs time <3 days) and monocytopenia (OR, 2.49 [95% CI, 1.29-4.82]). Monocytosis was associated with lower risk of admission/transfer to ICUs (OR, 0.25 [95% CI, 0.05-1.13]).Conclusions Clinical and biological features on admission and time until admission were associated with admission to ICUs. Signs to predict worsening on admission could be partially associated with the time until admission. This finding reinforces the need for appropriate guidelines to manage COVID-19 patients in this time window.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04290780Clinical Protocols https://www.medrxiv.org/content/10.1101/2020.04.08.20057471v1 Funding StatementThe project was partially funded by REACTing (REsearch and ACTion targeting emerging infectious diseases)-INSERM, France.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national). Favorable approval of the Ile-de-France V Ethics committee on March 08, 2020 : 2020- A00546-33 Written informed consent was obtained from all patients for being included in the study. Data were analyzed anonymously. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.